Oral contraceptives and survival in breast cancer patients aged 20 to 54 years

Cancer Epidemiology Biomarkers and Prevention

Volumn 16, Issue 9, 2007, Pages 1822-1827

  Trivers, Katrina F ^a,g   Gammon, Marilie D ^a   Abrahamson, Page E ^a,b   Lund, Mary Jo ^c,d   Flagg, Elaine W ^d   Moorman, Patricia G ^e   Kaufman, Jay S ^a   Cai, Jianwen ^a   Porter, Peggy L ^b   Brinton, Louise A ^f   Eley, J William ^d   Coates, Ralph J ^d  

^a IL   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c EMORY UNIVERSITY   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; PREMENOPAUSE; PRIORITY JOURNAL;

ADULT; AGE FACTORS; AGING; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COHORT STUDIES; CONTRACEPTIVES, ORAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MENOPAUSE; MIDDLE AGED; QUESTIONNAIRES; RISK; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 34548842750     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-0053     Document Type: Article

References (40)

1. Mosher WD, Martinez GM, Chandra A, Abma JC, Willson SJ. Use of contraception and use of family planning services in the United States: 1982-2002. Advance data from vital and health statistics; No 350. Hyattsville (MD): National Center for Health Statistics; 2004.
2. Cogliano V, Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F. Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol 2005;6:552-3.
3. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996;347:1713-27.
4. Althuis MD, Brogan DR, Coates RJ, et al. Hormonal content and potency of oral contraceptives and breast cancer risk among young women. Br J Cancer 2003;88:50-7.
5. Spencer JD, Millis RR, Hayward JL. Contraceptive steroids and breast cancer. Br Med J 1978;1:1024-6.
6. Matthews PN, Millis RR, Hayward JL. Breast cancer in women who have taken contraceptive steroids. Br Med J (Clin Res Ed) 1981;282:774-6.
7. Vessey M, Baron J, Doll R, McPherson K, Yeates D. Oral contraceptives and breast cancer: final report of an epidemiological study. Br J Cancer 1983;47:455-62.
8. Greenberg ER, Vessey MP, McPherson K, Doll R, Yeates D. Body size and survival in premenopausal breast cancer. Br J Cancer 1985;51:691-7.
9. Rosner D, Lane WW. Oral contraceptive use has no adverse effect on the prognosis of breast cancer. Cancer 1986;57:591-6.
10. Millard FC, Bliss JM, Chilvers CE, Gazet JC. Oral contraceptives and survival in breast cancer. Br J Cancer 1987;56:377-8.
11. Mohle-Boetani JC, Grosser S, Whittemore AS, Malec M, Kampert JB, Paffenbarger RS, Jr. Body size, reproductive factors, and breast cancer survival. Prev Med 1988;17:634-42.
12. Olsson H, Moller T, Ranstam J, Borg A, Ferno M. Early oral contraceptive use as a prognostic factor in breast cancer. Anticancer Res 1988;8:29-32.
13. Lees AW, Jenkins HJ, May CL, Cherian G, Lam EW, Hanson J. Risk factors and 10-year breast cancer survival in northern Alberta. Breast Cancer Res Treat 1989;13:143-51.
14. Ewertz M, Gillanders S, Meyer L, Zedeler K. Survival of breast cancer patients in relation to factors which affect the risk of developing breast cancer. Int J Cancer 1991;49:526-30.
15. Ranstam J, Olsson H, Garne JP, Aspegren K, Janzon L. Survival in breast cancer and age at start of oral contraceptive usage. Anticancer Res 1991;11:2043-6.
16. Holmberg L, Lund E, Bergstrom R, Adami HO, Meirik O. Oral contraceptive and prognosis in breast cancer: effects of duration, latency, recency, age at first use and relation to parity and body mass index in young women with breast cancer. Eur J Cancer 1994;30A:351-4.
17. Schonborn I, Nischan P, Ebeling K. Oral contraceptive use and the prognosis of breast cancer. Breast Cancer Res Treat 1994;30:283-92.
18. Schouten LJ, Hupperets PS, Jager JJ, et al. Prognostic significance of etiological risk factors in early breast cancer. Breast Cancer Res Treat 1997;43:217-23.
19. Sauerbrei W, Blettner M, Schmoor C, Bojar H, Schumacher M. The effect of oral contraceptive use on the prognosis of node positive breast cancer patients. Eur J Cancer 1998;34:1348-51.
20. Saxe GA, Rock CL, Wicha MS, Schottenfeld D. Diet and risk for breast cancer recurrence and survival. Breast Cancer Res Treat 1999;53:241-53.
21. Reeves GK, Patterson J, Vessey MP, Yeates D, Jones L. Hormonal and other factors in relation to survival among breast cancer patients. Int J Cancer 2000;89:293-9.
22. Gonzalez-Angulo AM, Broglio K, Kau SW, et al. Women age < or = 35 years with primary breast carcinoma: disease features at presentation. Cancer 2005;103:2466-72.
23. Ries LAG, Harkins D, Krapcho M, et al. editors. SEER Cancer Statistics Review, 1975-2003, National Cancer Institute. Bethesda, MD, http://seer.cancer. gov/csr/1975_2003/, based on November 2005 SEER data submission, posted to the SEER web site, 2006.
24. Whiteman MK, Hillis SD, Curtis KM, McDonald JA, Wingo PA, Marchbanks PA. Body mass and mortality after breast cancer diagnosis. Cancer Epidemiol Biomarkers Prev 2005;14:2009-14.
25. Brinton LA, Daling JR, Liff JM, et al. Oral contraceptives and breast cancer risk among younger women. J Natl Cancer Inst 1995;87:827-35.
26. Piper JM, Kennedy DL. Oral contraceptives in the United States: trends in content and potency. Int J Epidemiol 1987;16:215-21.
27. Shambaugh EM, Weiss MA, Axtell LM, editors. Summary Staging Guide for the Cancer Surveillance, Epidemiology, and End Results Reporting (SEER) Program, 1977.
28. Fleming ID, Cooper JS, Henson DE, editors. American Joint Committee on Cancer Staging manual. Philadelphia: Lippincott-Raven; 1997.
29. Cox D. Regression models and life tables. J R Stat Soc 1972;34:187-220.
30. Sington JD, Cottrell BJ. Analysis of the sensitivity of death certificates in 440 hospital deaths: a comparison with necropsy findings. J Clin Pathol 2002;55:499-502.
31. Hatcher R, Trussell J, Stewart F, et al. Contraceptive technology. New York: Ardent Media, Inc.; 2004.
32. Drug facts and comparisons, 2004 edition. St. Louis: Wolters Kluwer Health.
33. Drug facts and comparisons, 2006 edition. St. Louis: Wolters Kluwer Health.
34. Kroenke CH, Chen WY, Rosner B, Holmes MD. Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol 2005;23:1370-8.
35. Chirikos TN, Russell-Jacobs A, Cantor AB. Indirect economic effects of long-term breast cancer survival. Cancer Pract 2002;10:248-55.
36. Coulter A, Vessey M, McPherson K, Crossley B. The ability of women to recall their oral contraceptive histories. Contraception 1986;33:127-37.
37. Norell SE, Boethius G, Persson I. Oral contraceptive use: interview data versus pharmacy records. Int J Epidemiol 1998;27:1033-7.
38. Rich-Edwards J, Corsano K, Stampfer M. Test of the National Death Index and Equifax national search. Am J Epidemiol 1994;140:1016-9.
39. Lash TL, Silliman RA, Guadagnoli E, Mor V. The effect of less than definitive care on breast carcinoma recurrence and mortality. Cancer 2000;89:1739-47.
40. Madigan MP, Troisi R, Potischman N, et al. Characteristics of respondents and non-respondents from a case-control study of breast cancer in younger women. Int J Epidemiol 2000;29:793-8.